Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2025-08-14 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 second extraordinary general meeting of shareholders (临时股东大会) for Jiangsu Haobo Biopharmaceutical Co., Ltd. It includes information about the meeting date, voting methods (including cumulative voting), agenda items such as changing the audit firm and electing independent directors, instructions for shareholders on registration and voting, and attachments related to proxy forms and voting procedures. The document is not a report of financial results, audit, or management discussion, but rather a formal announcement and detailed notice of a shareholders meeting with agenda and voting instructions. It does not contain financial statements or earnings data. This fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. The document length (4568 characters) and content confirm it is the meeting notice and proxy information rather than a brief announcement or a report publication announcement. Therefore, the correct classification is PSI with high confidence.
2025-08-14 Chinese
江苏浩欧博生物医药股份有限公司董事会提名委员会关于第三届董事会独立董事候选人任职资格的审查意见
Board/Management Information Classification · 100% confidence The document is a formal opinion from the Board Nomination Committee regarding the qualifications of independent director candidates for the company's third board. It references relevant laws and regulations about director qualifications and independence, and concludes with a nomination recommendation to the board. There is no financial data, no mention of financial results, no shareholder voting results, no meeting materials, and no regulatory filings or announcements about reports. The content is specifically about board/management information, particularly the nomination and qualification of directors. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and focused on management nomination, not a report or announcement of a report.
2025-08-14 Chinese
江苏浩欧博生物医药股份有限公司关于独立董事离任及补选独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of independent directors and the nomination of new independent director candidates for the company's board. It details the names, reasons for departure, and qualifications of the new candidates. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a report announcement, but a formal disclosure of management changes.
2025-08-14 Chinese
江苏浩欧博生物医药股份有限公司2025年度“提质增效重回报”专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2025年度‘提质增效重回报’专项行动方案的半年度评估报告" which translates to a "2025 Half-Year Evaluation Report on the Special Action Plan for Quality Improvement, Efficiency Enhancement, and Return." It contains detailed operational and financial performance data for the first half of 2025, including revenue, net profit, R&D investment, and strategic initiatives. The report also discusses dividend distribution completed in May 2025 and governance activities such as board committee meetings. The document is comprehensive and covers a half-year period with substantive financial data and management commentary, fitting the definition of an Interim / Quarterly Report (IR). The document length is 2334 characters, which is relatively short but contains actual financial data and analysis, not just an announcement or summary. Therefore, it is classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-14 Chinese
独立董事提名人声明与承诺（彭建刚）
Board/Management Information Classification · 100% confidence The document is a formal statement and commitment from a nominator regarding the nomination of an independent director candidate for the company's board. It details the qualifications, compliance with legal and regulatory requirements, and the independence of the nominee. There is no financial data, no report of financial results, no voting results, no announcement of a report publication, nor any other type of financial or regulatory filing. The content is specifically about board/management information related to the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and focused on nomination, not a full report or announcement of voting results.
2025-08-14 Chinese
独立董事候选人声明与承诺（彭建刚）
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate for a company's board, detailing qualifications, independence criteria, and compliance with regulatory requirements. It is not a financial report, earnings release, or any form of meeting material. It does not announce changes in management but is a formal statement related to board candidate qualifications. This type of document fits best under Board/Management Information (MANG), which covers announcements related to board members and senior management, including candidate declarations.
2025-08-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.